Banco de Sabadell S.A acquired a new position in Eli Lilly and Co (NYSE:LLY) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 15,711 shares of the company’s stock, valued at approximately $1,326,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Gradient Investments LLC bought a new stake in Eli Lilly and during the fourth quarter valued at about $103,000. Avestar Capital LLC bought a new stake in Eli Lilly and during the fourth quarter valued at about $100,000. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and during the second quarter valued at about $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and during the second quarter valued at about $129,000. Finally, Willingdon Wealth Management bought a new stake in Eli Lilly and during the third quarter valued at about $138,000. 77.62% of the stock is owned by institutional investors.
Eli Lilly and Co (NYSE LLY) opened at $76.53 on Friday. Eli Lilly and Co has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a market capitalization of $85,862.01, a PE ratio of -382.63, a PEG ratio of 1.46 and a beta of 0.28. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.32 and a quick ratio of 1.01.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the previous year, the business earned $0.95 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. sell-side analysts predict that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
Several research firms have issued reports on LLY. TheStreet lowered Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Jefferies Group set a $93.00 price target on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. JPMorgan Chase & Co. set a $105.00 price target on Eli Lilly and and gave the company a “buy” rating in a report on Monday, February 26th. Credit Suisse Group reissued a “hold” rating and set a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. Finally, Bank of America cut their price target on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, February 1st. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $93.47.
In other news, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $79.20, for a total value of $237,600.00. Following the completion of the transaction, the chief financial officer now owns 20,029 shares in the company, valued at $1,586,296.80. The disclosure for this sale can be found here. Insiders sold 15,261 shares of company stock worth $1,225,085 over the last 90 days. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.